Go to the list of all blogs
Nataliia Wilson's Avatar
published in Blogs
Aug 06, 2026
Celsius Holdings (CELH) Stock Faces Headwinds After Q2 Miss and -47% YTD Decline

Celsius Holdings (CELH) Stock Faces Headwinds After Q2 Miss and -47% YTD Decline

Key Takeaways

  • Celsius Holdings shares closed at $29.15 on August 5, 2026, reflecting a decline of approximately 8% over the trailing 30-day period and a steeper drop of roughly 47% year-to-date.
  • Second-quarter 2026 revenue of $817.9 million missed analyst estimates by roughly 6%, while adjusted EPS of $0.36 fell well short of the $0.42–$0.43 consensus, triggering a sharp post-earnings selloff.
  • The flagship CELSIUS brand posted an 11.7% year-over-year revenue decline, pressured by promotional spending, inventory rebalancing, and softness in the club channel.
  • Acquired brands Alani Nu and Rockstar Energy contributed $364.4 million and $66.5 million in quarterly revenue, respectively, underscoring the company's transition into a multi-brand portfolio.
  • Gross margins contracted to 48.1% from 51.5% a year ago, weighed by higher promotional activity and aluminum cost inflation, though management expects margin initiatives to gain traction in the second half of 2026.

Market Snapshot for CELH

Celsius Holdings entered August 2026 under significant pressure. The stock closed at $29.15 on August 5, capping a 30-day period in which shares drifted approximately 8% lower from the $31.70 level recorded in early July. The broader trend has been even more challenging: year-to-date, CELH has shed roughly 47%, sharply underperforming the broader market. Sentiment soured further after the company reported second-quarter results on August 6 that missed both top- and bottom-line expectations, sending shares down an additional 15.9% in post-earnings trading. The stock sits near levels not seen since early 2025, as investors reassess the pace of portfolio integration and the health of the core Celsius brand. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Celsius Holdings' Brand Portfolio and Competitive Position

Celsius Holdings is a functional beverage company operating three distinct energy drink brands: CELSIUS, its flagship zero-sugar fitness-oriented energy drink; Alani Nu, a health-and-wellness brand acquired in April 2025; and Rockstar Energy, added through the acquisition of Big Beverages Contract Manufacturing in August 2025. The company's products are distributed through a broad network that includes PepsiCo's distribution system for Alani Nu, as well as major retailers, club stores, and foodservice outlets across North America and international markets. The combined portfolio held approximately 20.1% dollar share of the U.S. ready-to-drink energy category in the second quarter and contributed roughly 30% of the zero-sugar energy category's dollar growth during the period. With two billion-dollar brands under one roof, Celsius Holdings has emerged as a scaled player in the global energy drink market.

Recent Developments Driving CELH

The most consequential recent event for CELH was the release of second-quarter 2026 financial results on August 6. Revenue grew 10.6% year-over-year to $817.9 million, yet came in meaningfully below the consensus estimate of approximately $885–887 million. Adjusted earnings per share of $0.36 missed forecasts by roughly 14–16%. The flagship CELSIUS brand saw revenue decline 11.7% compared to the same period in 2025, reflecting elevated trade and promotional spending, shipment timing tied to inventory rebalancing, softness in the club channel, and SKU optimization initiatives linked to the integration of Alani Nu and Rockstar. On a more positive note, Alani Nu generated $364.4 million in quarterly sales, buoyed by strong consumer demand, expanded PepsiCo distribution, and a successful limited-time flavor launch. Rockstar Energy contributed $66.5 million. Gross margin contracted by 340 basis points year-over-year to 48.1%, driven by higher promotional activity and commodity cost inflation, particularly in aluminum. International revenue rose 10% to $27.2 million, led by growth in Nordic markets and expansion into the UK, Ireland, France, and Australia. The company also repurchased approximately $100.4 million in shares during the quarter, signaling management confidence in long-term value creation.

2026 Outlook and What Investors Should Watch

Looking ahead, the remainder of 2026 presents several critical monitoring points for Celsius Holdings. The company's ability to stabilize and return the flagship CELSIUS brand to sustainable growth remains central to the investment case, and management commentary around SKU optimization results, distribution productivity, and promotional strategy will be closely scrutinized. Margin recovery initiatives—including freight optimization, raw material alignment, and revenue-growth-management capabilities—are expected to progressively offset commodity headwinds, but the pace of improvement will be a key differentiator. The Alani Nu brand's continued expansion through PepsiCo's distribution network represents a major growth lever, while Rockstar's stabilization trajectory will be watched for signs of contribution margin improvement. On the macro front, aluminum costs, consumer discretionary spending trends, and competitive dynamics within the energy drink category all carry implications for the stock's trajectory. The next quarterly earnings report will serve as an important checkpoint for whether the multi-brand portfolio strategy is delivering on its promise of durable, diversified growth.

Enhancing Research with Tickeron AI Tools

In my ongoing analysis of market signals and trading strategies, I often review Tickeron’s Trending AI Robots page. It curates top-performing AI-powered bots across various time horizons and approaches, providing a streamlined view of where data-driven sentiment is concentrated right now. This helps complement fundamental research with a real-time snapshot of relevant trading signals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CELH

CELH in downward trend: price may decline as a result of having broken its higher Bollinger Band on July 01, 2026

CELH broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In of the 39 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

CELH moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CELH crossed bearishly below the 50-day moving average on July 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CELH entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on CELH as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CELH just turned positive on August 04, 2026. Looking at past instances where CELH's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CELH advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CELH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.959) is normal, around the industry mean (6.886). P/E Ratio (67.791) is within average values for comparable stocks, (43.794). Projected Growth (PEG Ratio) (0.297) is also within normal values, averaging (4.588). CELH's Dividend Yield (0.000) is considerably lower than the industry average of (0.026). P/S Ratio (2.559) is also within normal values, averaging (3.019).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Notable companies

The most notable companies in this group are Coca-Cola Company (NYSE:KO), PepsiCo (NASDAQ:PEP).

Industry description

Non-alcoholic drinks include traces of alcohol or low alcohol content or without alcohol or alcohol removed. Functional Beverages, Carbonated Soft Drinks (CSDs), Sports Drinks, Fruit Beverages, and Bottled Water are some common types of non-alcoholic beverages. The largest segment in this market is soft drinks (think Pepsi and Coke). Many established companies in this space have also been stepping up production of low to zero-calorie varieties in recent years, to cater to a rising number of health-conscious consumers. Coca-Cola Company, Pepsico Inc, Keurig Dr Pepper Inc. and Monster Beverage Corporation are some major non-alcoholic beverage makers.

Market Cap

The average market capitalization across the Beverages: Non-Alcoholic Industry is 47.24B. The market cap for tickers in the group ranges from 1.77K to 373.59B. KO holds the highest valuation in this group at 373.59B. The lowest valued company is BVNNF at 1.77K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Non-Alcoholic Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -8%. PRMB experienced the highest price growth at 10%, while SUJA experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Beverages: Non-Alcoholic Industry was 1%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 66
Price Growth Rating: 59
SMR Rating: 61
Profit Risk Rating: 72
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
CELH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company which engages in development, marketing of beverages

Industry BeveragesNonAlcoholic

Profile
Details
Industry
Beverages Non Alcoholic
Address
2381 Northwest Executive Center Drive
Phone
+1 561 276-2239
Employees
1497
Web
https://www.celsius.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.